Efficacy and Rebound Effects of Repeated Low‐Level Red Light versus High‐Concentration Atropine for Myopia Control in Children: A Randomized Controlled Trial
Clinical & Experimental Ophthalmology · 2026-07 · 54 (5) · 605-616
DOI: 10.1111/ceo.70101 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 08.03.2026. Verfasst von Jiamin Xie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Red Light, Myopia, Atropine, Mydriatics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
To compare the efficacy of repeated low‐level red light (RLRL) and high‐concentration atropine (HCA, 1%) in myopia control and evaluate rebound effects after cessation.
Methods
In this 15‐month, prospective, single‐blinded randomized controlled trial, 136 myopic children (6–12 years) were randomly assigned to RLRL or HCA (1:1). Treatment lasted 12 months followed by a 3‐month washout. Outcomes included change in axial length (AL), spherical equivalent refraction (SER), subfoveal choroidal thickness (SFChT), and safety.
Results
A total of 116 children completed ≥ 1 follow‐up (RLRL: 65, HCA: 51). At 12 months, RLRL showed superior efficacy: AL regressed by −0.014 mm (95% CI: −0.067 to 0.039) versus a 0.094 mm increase with HCA (95% CI: 0.046–0.141; p = 0.005). SER decreased by 0.24 D (95% CI: 0.093–0.387) in RLRL and increased by 0.035 D (95% CI: −0.154 to 0.083) in HCA ( p = 0.008), while SFChT increased by 26.000 μm (95% CI: 18.082–33.918) and 12.761 μm (95% CI: 3.867–21.655; p = 0.032), respectively. During the 3‐month washout, AL elongation was slightly greater in RLRL (0.163 mm) compared to HCA (0.115 mm; p = 0.014). Higher compliance (≥ 75%) with RLRL correlated with better 12‐month efficacy (AL: −0.064 mm vs. 0.084 mm; p = 0.011) but worse rebound (AL: 0.183 mm vs. 0.122 mm; p = 0.02). No severe adverse events were reported.
Conclusions
RLRL exhibited superior 12‐month efficacy over HCA (1%) but was associated with slightly higher rebound. Optimizing RLRL regimens, including implementing reduced dosing and tapered withdrawal, could sustain benefits while limiting rebound. Trial Registration Chinese Clinical Trial Registry: ChiCTR2100051940
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- National Clinical Research Center for Eye Diseases, Shanghai, China.
- Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China.
- Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China.
- Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, China.
- Penn Medicine Doylestown Health, Doylestown, Pennsylvania, USA.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xie, J., Zhang, Z., Zhang, T., Xie, D., Xu, X., & Lu, Y. (2026). Efficacy and Rebound Effects of Repeated Low‐Level Red Light versus High‐Concentration Atropine for Myopia Control in Children: A Randomized Controlled Trial. Clinical & Experimental Ophthalmology, 54(5), 605-616. https://doi.org/10.1111/ceo.70101
Vancouver
Xie J, Zhang Z, Zhang T, Xie D, Xu X, Lu Y. Efficacy and Rebound Effects of Repeated Low‐Level Red Light versus High‐Concentration Atropine for Myopia Control in Children: A Randomized Controlled Trial. Clinical & Experimental Ophthalmology. 2026;54(5):605-616. doi:10.1111/ceo.70101
BibTeX
@article{Xie2026,
author = {Xie, Jiamin and Zhang, Zhihua and Zhang, Ting and Xie, Dawei and Xu, Xun and Lu, Yi},
title = {Efficacy and Rebound Effects of Repeated Low‐Level Red Light versus High‐Concentration Atropine for Myopia Control in Children: A Randomized Controlled Trial},
journal = {Clinical & Experimental Ophthalmology},
year = {2026},
volume = {54},
number = {5},
pages = {605--616},
doi = {10.1111/ceo.70101}
}
EUVIMED